O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS
Annals of Oncology(2023)
Abstract
We conducted an investigator-initiated, multi-institutional first-in-human phase I clinical trial of a NY-ESO-1-specific TCR engineered T cell (TBI-1301) combined with a T cell stimulator CHP:NE1 for patients with NY-ESO-1-expressing advanced soft tissue sarcoma (STS).
MoreTranslated text
Key words
nanoparticulate vaccine,lymphodepletion,ny-eso
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined